Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Thomas O'Donnell, MD
Benjamin Andrews Chair of Surgery Emeritus
Tufts Medical Center
Boston, MA
Benjamin Andrews Chair of Surgery Emeritus
Tufts Medical Center
Boston, MA
Authored Items
Evaluating the Expected Costs and Budget Impact of Interventional Therapies for the Treatment of Chronic Venous Disease
Rashad Carlton, PharmD, MSPH
,
Rajiv Mallick, PhD
,
Chelsey Campbell, PharmD, MBA
,
Aditya Raju, MS, BPharm
,
Thomas O'Donnell, MD
,
Michael Eaddy, PharmD, PhD
,
Michael F. Murphy, MD, PhD
,
Michael Eaddy, PharmD, PhD
,
Michael F. Murphy, MD, PhD
October 2015 Vol 8, No 7
in
Original Research
,
Practice Management
Last modified: October 19, 2015